Company / Gross Margin
Haemonetics Gross Margin History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
55.0%
FY2024
5-year range
50.9% / 55.0%
FY2020-FY2024
Trend
+4.2%
vs FY2023
Sector context
#52 of 91
Health Care
What the data says
At 55.0%, Haemonetics's gross margin ranks #52 of 91 in the Health Care sector. Gross Margin has increased for 3 consecutive years, from 50.9% in FY2021 to 55.0% in FY2024.
Based on SEC 10-K filings.
55.0% in FY2024 with a 3-year CAGR of +4.1%.
Improved from 52.6% to 55.0% over the past 2 years.
Health Care sector context is included.
Gross Margin over time
Growth rates
- 3-Year Change
- +4.1pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
#52 of 91 in Health CareTop 57% of 91This company 55.0% Sector average 53.8%
▼
+2.3% above sector average
Key checks
Key Insights
- Haemonetics's gross margin has grown for 3 consecutive years.
- In FY2024, gross margin increased 4.2% year-over-year.
- Currently 1.2pp above the Health Care sector average.
- Peak gross margin was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | 55.0% | +4.2% |
| FY2023 | 52.8% | +0.4% |
| FY2022 | 52.6% | +3.4% |
| FY2021 | 50.9% | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | 182.8% | +327.9% |
| FY2016 | 42.7% | -4.4% |
As of FY2024 · SEC 10-K · Updated Mar 28, 2026